Medarex Announces Presentations at Annual Meeting of the American Society of Clinica...(l time on Sunday June 1 2008. -...),Health

2008.

-- "Effect of a fully human anti-CD70 antibody on apoptosis and

dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"

(Abstract #3073, Developmental Therapeutics: Immunotherapy

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Sunday, June 1, 2008.

More information about the ASCO Annual Meeting may be found at http://www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.